Effects of Ginkgo biloba extracts on pharmacokinetics and efficacy of atorvastatin based on plasma indices

References

• Amundsen R, Christensen H, Zabihyan B, Asberg A. (2010). Cyclosporine A, but not tacrolimus, shows relevant inhibition of organic anion-transporting protein 1B1-mediated transport of atorvastatin. Drug Metab Dispos 38:1499–1504.
   PubMed Web of Science ®Google Scholar
• Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, Kirby A, Sourjina T, Peto R, Collins R, Simes R; Cholesterol Treatment Trialists’ (CTT) Collaborators. (2005). Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 366:1267–1278.
   PubMed Web of Science ®Google Scholar
• Bays HE, Dujovne CA. (1998). Drug interactions of lipid-altering drugs. Drug Saf 19:355–371.
   PubMed Web of Science ®Google Scholar
• Diamond BJ, Shiflett SC, Feiwel N, Matheis RJ, Noskin O, Richards JA, Schoenberger NE. (2000). Ginkgo biloba extract: mechanisms and clinical indications. Arch Phys Med Rehabil 81:668–678.
   PubMed Web of Science ®Google Scholar
• Goosen TC, Bauman JN, Davis JA, Yu C, Hurst SI, Williams JA, Loi CM. (2007). Atorvastatin glucuronidation is minimally and nonselectively inhibited by the fibrates gemfibrozil, fenofibrate, and fenofibric acid. Drug Metab Dispos 35:1315–1324.
   PubMed Web of Science ®Google Scholar
• Greenblatt DJ, von Moltke LL, Luo Y, Perloff ES, Horan KA, Bruce A, Reynolds RC, Harmatz JS, Avula B, Khan IA, Goldman P. (2006). Ginkgo biloba does not alter clearance of flurbiprofen, a cytochrome P450-2C9 substrate. J Clin Pharmacol 46:214–221.
   PubMed Web of Science ®Google Scholar
• Gurley BJ, Gardner SF, Hubbard MA, Williams DK, Gentry WB, Cui Y, Ang CY. (2002). Cytochrome P450 phenotypic ratios for predicting herb-drug interactions in humans. Clin Pharmacol Ther 72:276–287.
   PubMed Web of Science ®Google Scholar
• Gurley BJ, Gardner SF, Hubbard MA, Williams DK, Gentry WB, Cui Y, Ang CY. (2005). Clinical assessment of effects of botanical supplementation on cytochrome P450 phenotypes in the elderly: St John’s wort, garlic oil, Panax ginseng and Ginkgo biloba. Drugs Aging 22:525–539.
   PubMed Web of Science ®Google Scholar
• Haag MD, Hofman A, Koudstaal PJ, Stricker BH, Breteler MM. (2009). Statins are associated with a reduced risk of Alzheimer disease regardless of lipophilicity. The Rotterdam Study. J Neurol Neurosurg Psychiatr 80:13–17.
   PubMed Web of Science ®Google Scholar
• He YJ, Zhang W, Chen Y, Guo D, Tu JH, Xu LY, Tan ZR, Chen BL, Li Z, Zhou G, Yu BN, Kirchheiner J, Zhou HH. (2009). Rifampicin alters atorvastatin plasma concentration on the basis of SLCO1B1 521T>C polymorphism. Clin Chim Acta 405:49–52.
   PubMed Web of Science ®Google Scholar
• Heinemann T, Axtmann G, von Bergmann K. (1993). Comparison of intestinal absorption of cholesterol with different plant sterols in man. Eur J Clin Invest 23:827–831.
   PubMed Web of Science ®Google Scholar
• Hoenig MR, Walker PJ, Gurnsey C, Beadle K, Johnson L. (2010). Markers of cholesterol absorption and synthesis predict the low-density lipoprotein cholesterol response to atorvastatin. J Cardiovasc Pharmacol 56:396–401.
   PubMedGoogle Scholar
• Ieiri I, Suwannakul S, Maeda K, Uchimaru H, Hashimoto K, Kimura M, Fujino H, Hirano M, Kusuhara H, Irie S, Higuchi S, Sugiyama Y. (2007). SLCO1B1 (OATP1B1, an uptake transporter) and ABCG2 (BCRP, an efflux transporter) variant alleles and pharmacokinetics of pitavastatin in healthy volunteers. Clin Pharmacol Ther 82:541–547.
   PubMed Web of Science ®Google Scholar
• Igel M, Sudhop T, von Bergmann K. (2001). Metabolism and drug interactions of 3-hydroxy-3-methylglutaryl coenzyme A-reductase inhibitors (statins). Eur J Clin Pharmacol 57:357–364.
   PubMed Web of Science ®Google Scholar
• Jacobson TA. (2004). Comparative pharmacokinetic interaction profiles of pravastatin, simvastatin, and atorvastatin when coadministered with cytochrome P450 inhibitors. Am J Cardiol 94:1140–1146.
   PubMed Web of Science ®Google Scholar
• Jaracz S, Malik S, Nakanishi K. (2004). Isolation of ginkgolides A, B, C, J and bilobalide from G. biloba extracts. Phytochemistry 65:2897–2902.
   PubMedGoogle Scholar
• Jemal M, Ouyang Z, Chen BC, Teitz D. (1999). Quantitation of the acid and lactone forms of atorvastatin and its biotransformation products in human serum by high-performance liquid chromatography with electrospray tandem mass spectrometry. Rapid Commun Mass Spectrom 13:1003–1015.
   PubMed Web of Science ®Google Scholar
• Jiang X, Williams KM, Liauw WS, Ammit AJ, Roufogalis BD, Duke CC, Day RO, McLachlan AJ. (2005). Effect of ginkgo and ginger on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects. Br J Clin Pharmacol 59:425–432.
   PubMed Web of Science ®Google Scholar
• Kameyama Y, Yamashita K, Kobayashi K, Hosokawa M, Chiba K. (2005). Functional characterization of SLCO1B1 (OATP-C) variants, SLCO1B1*5, SLCO1B1*15 and SLCO1B1*15+C1007G, by using transient expression systems of HeLa and HEK293 cells. Pharmacogenet Genomics 15:513–522.
   PubMed Web of Science ®Google Scholar
• Keskitalo JE, Kurkinen KJ, Neuvoneni PJ, Niemi M. (2008). ABCB1 haplotypes differentially affect the pharmacokinetics of the acid and lactone forms of simvastatin and atorvastatin. Clin Pharmacol Ther 84:457–461.
   PubMed Web of Science ®Google Scholar
• Keskitalo JE, Zolk O, Fromm MF, Kurkinen KJ, Neuvonen PJ, Niemi M. (2009). ABCG2 polymorphism markedly affects the pharmacokinetics of atorvastatin and rosuvastatin. Clin Pharmacol Ther 86:197–203.
   PubMed Web of Science ®Google Scholar
• Lau AJ, Yang G, Rajaraman G, Baucom CC, Chang TK. (2010). Human pregnane X receptor agonism by Ginkgo biloba extract: assessment of the role of individual ginkgolides. J Pharmacol Exp Ther 335:771–780.
   PubMed Web of Science ®Google Scholar
• Lau YY, Huang Y, Frassetto L, Benet LZ. (2007). Effect of OATP1B transporter inhibition on the pharmacokinetics of atorvastatin in healthy volunteers. Clin Pharmacol Ther 81:194–204.
   PubMed Web of Science ®Google Scholar
• Lee YJ, Lee MG, Lim LA, Jang SB, Chung JY. (2010). Effects of SLCO1B1 and ABCB1 genotypes on the pharmacokinetics of atorvastatin and 2-hydroxyatorvastatin in healthy Korean subjects. Int J Clin Pharmacol Ther 48:36–45.
   PubMed Web of Science ®Google Scholar
• Lei HP, Ji W, Lin J, Chen H, Tan ZR, Hu DL, Liu LJ, Zhou HH. (2009). Effects of Ginkgo biloba extract on the pharmacokinetics of bupropion in healthy volunteers. Br J Clin Pharmacol 68:201–206.
   PubMed Web of Science ®Google Scholar
• Lennernäs H. (2003). Clinical pharmacokinetics of atorvastatin. Clin Pharmacokinet 42:1141–1160.
   PubMed Web of Science ®Google Scholar
• Li L, Stanton JD, Tolson AH, Luo Y, Wang H. (2009). Bioactive terpenoids and flavonoids from Ginkgo biloba extract induce the expression of hepatic drug-metabolizing enzymes through pregnane X receptor, constitutive androstane receptor, and aryl hydrocarbon receptor-mediated pathways. Pharm Res 26:872–882.
   PubMed Web of Science ®Google Scholar
• Link E, Parish S, Armitage J, Bowman L, Heath S, Matsuda F, Gut I, Lathrop M, Collins R; SEARCH Collaborative Group. (2008). SLCO1B1 variants and statin-induced myopathy–a genomewide study. N Engl J Med 359:789–799.
   PubMed Web of Science ®Google Scholar
• Luo Y. (2006). Alzheimer’s disease, the nematode Caenorhabditis elegans, and Ginkgo biloba leaf extract. Life Sci 78:2066–2072.
   PubMed Web of Science ®Google Scholar
• Lütjohann D, Björkhem I, Beil UF, von Bergmann K. (1995). Sterol absorption and sterol balance in phytosterolemia evaluated by deuterium-labeled sterols: effect of sitostanol treatment. J Lipid Res 36:1763–1773.
   PubMed Web of Science ®Google Scholar
• Markowitz JS, Donovan JL, Lindsay DeVane C, Sipkes L, Chavin KD. (2003). Multiple-dose administration of Ginkgo biloba did not affect cytochrome P-450 2D6 or 3A4 activity in normal volunteers. J Clin Psychopharmacol 23:576–581.
   PubMed Web of Science ®Google Scholar
• Neuvonen PJ, Niemi M, Backman JT. (2006). Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance. Clin Pharmacol Ther 80:565–581.
   PubMed Web of Science ®Google Scholar
• Niemi M, Neuvonen PJ, Hofmann U, Backman JT, Schwab M, Lütjohann D, von Bergmann K, Eichelbaum M, Kivistö KT. (2005). Acute effects of pravastatin on cholesterol synthesis are associated with SLCO1B1 (encoding OATP1B1) haplotype *17. Pharmacogenet Genomics 15:303–309.
   PubMed Web of Science ®Google Scholar
• Niemi M, Pasanen MK, Neuvonen PJ. (2006). SLCO1B1 polymorphism and sex affect the pharmacokinetics of pravastatin but not fluvastatin. Clin Pharmacol Ther 80:356–366.
   PubMed Web of Science ®Google Scholar
• Park JE, Kim KB, Bae SK, Moon BS, Liu KH, Shin JG. (2008). Contribution of cytochrome P450 3A4 and 3A5 to the metabolism of atorvastatin. Xenobiotica 38:1240–1251.
   PubMed Web of Science ®Google Scholar
• Pasanen MK, Fredrikson H, Neuvonen PJ, Niemi M. 2007. Different effects of SLCO1B1 polymorphism on the pharmacokinetics of atorvastatin and rosuvastatin. Clin Pharmacol Ther 82:726–733.
   PubMed Web of Science ®Google Scholar
• Pasanen MK, Miettinen TA, Gylling H, Neuvonen PJ, Niemi M. 2008. Polymorphism of the hepatic influx transporter organic anion transporting polypeptide 1B1 is associated with increased cholesterol synthesis rate. Pharmacogenet Genomics 18:921–926.
   PubMed Web of Science ®Google Scholar
• Pasanen MK, Neuvonen M, Neuvonen PJ, Niemi M. 2006. SLCO1B1 polymorphism markedly affects the pharmacokinetics of simvastatin acid. Pharmacogenet Genomics 16:873–879.
   PubMed Web of Science ®Google Scholar
• Prueksaritanont T, Subramanian R, Fang X, Ma B, Qiu Y, Lin JH, Pearson PG, Baillie TA. (2002). Glucuronidation of statins in animals and humans: a novel mechanism of statin lactonization. Drug Metab Dispos 30:505–512.
   PubMed Web of Science ®Google Scholar
• Reddy P, Ellington D, Zhu Y, Zdrojewski I, Parent SJ, Harmatz JS, Derendorf H, Greenblatt DJ, Browne K Jr. (2011). Serum concentrations and clinical effects of atorvastatin in patients taking grapefruit juice daily. Br J Clin Pharmacol 72:434–441.
   PubMed Web of Science ®Google Scholar
• Riedmaier S, Klein K, Hofmann U, Keskitalo JE, Neuvonen PJ, Schwab M, Niemi M, Zanger UM. (2010). UDP-glucuronosyltransferase (UGT) polymorphisms affect atorvastatin lactonization in vitro and in vivo. Clin Pharmacol Ther 87:65–73.
   PubMed Web of Science ®Google Scholar
• Robertson SM, Davey RT, Voell J, Formentini E, Alfaro RM, Penzak SR. (2008). Effect of Ginkgo biloba extract on lopinavir, midazolam and fexofenadine pharmacokinetics in healthy subjects. Curr Med Res Opin 24:591–599.
   PubMed Web of Science ®Google Scholar
• Shin KH, Kim TE, Kim SE, Lee MG, Song IS, Yoon SH, Cho JY, Jang IJ, Shin SG, Yu KS. (2011). The effect of the newly developed angiotensin receptor II antagonist fimasartan on the pharmacokinetics of atorvastatin in relation to OATP1B1 in healthy male volunteers. J Cardiovasc Pharmacol 58:492–499.
   PubMed Web of Science ®Google Scholar
• Uno T, Yasui-Furukori N. (2006). Effect of grapefruit juice in relation to human pharmacokinetic study. Curr Clin Pharmacol 1:157–161.
   PubMedGoogle Scholar
• von Moltke LL, Weemhoff JL, Bedir E, Khan IA, Harmatz JS, Goldman P, Greenblatt DJ. (2004). Inhibition of human cytochromes P450 by components of Ginkgo biloba. J Pharm Pharmacol 56:1039–1044.
   PubMed Web of Science ®Google Scholar
• Whitfield LR, Porcari AR, Alvey C, Abel R, Bullen W, Hartman D. (2011). Effect of gemfibrozil and fenofibrate on the pharmacokinetics of atorvastatin. J Clin Pharmacol 51:378–388.
   PubMed Web of Science ®Google Scholar
• Williams D, Feely J. (2002). Pharmacokinetic-pharmacodynamic drug interactions with HMG-CoA reductase inhibitors. Clin Pharmacokinet 41:343–370.
   PubMed Web of Science ®Google Scholar
• Yasui-Furukori N, Furukori H, Kaneda A, Kaneko S, Tateishi T. (2004). The effects of Ginkgo biloba extracts on the pharmacokinetics and pharmacodynamics of donepezil. J Clin Pharmacol 44:538–542.
   PubMed Web of Science ®Google Scholar
• Yeung EY, Sueyoshi T, Negishi M, Chang TK. (2008). Identification of Ginkgo biloba as a novel activator of pregnane X receptor. Drug Metab Dispos 36:2270–2276.
   PubMed Web of Science ®Google Scholar
• Yoshioka M, Ohnishi N, Koishi T, Obata Y, Nakagawa M, Matsumoto T, Tagagi K, Takara K, Ohkuni T, Yokoyama T, Kuroda K. (2004). Studies on interactions between functional foods or dietary supplements and medicines. IV. Effects of Ginkgo biloba leaf extract on the pharmacokinetics and pharmacodynamics of nifedipine in healthy volunteers. Biol Pharm Bull 27:2006–2009.
   PubMed Web of Science ®Google Scholar
• Zuo XC, Zhang BK, Jia SJ, Liu SK, Zhou LY, Li J, Zhang J, Dai LL, Chen BM, Yang GP, Yuan H. (2010). Effects of Ginkgo biloba extracts on diazepam metabolism: a pharmacokinetic study in healthy Chinese male subjects. Eur J Clin Pharmacol 66:503–509.
   PubMed Web of Science ®Google Scholar